Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Prosthetic Embodiment Research Could Improve Outcomes After Amputation in Sarcomas

August 26th 2025

R. Lor Randall, MD, FACS, discusses prosthetic design, embodiment strategies, and research to enhance function post-amputation in sarcoma management.

BRF14 Data Demonstrate Long-Term Efficacy of Imatinib in Advanced GIST

August 22nd 2025

The BRF14 study, which examined imatinib in patients with gastrointestinal stromal tumors, has the longest follow-up time in this sarcoma.

Dr Randall on the Complexity of PEComas

August 19th 2025

R. Lor Randall, MD, FACS, discusses the complexity of perivascular epithelioid cell tumors and the critical importance of multidisciplinary care.

Anlotinib Plus Epirubicin Elicits PFS Benefit in Advanced Soft Tissue Sarcoma

August 19th 2025

Anlotinib plus epirubicin conferred a significant PFS benefit vs epirubicin monotherapy in advanced soft tissue sarcoma.

Nirogacestat Wins EU Approval for Progressing Desmoid Tumors

August 18th 2025

The European Commission approved nirogacestat for the treatment of progressing desmoid tumors requiring systemic treatment.

PLD Plus Ifosfamide Shows Promising Activity in Advanced Soft Tissue Sarcoma

August 17th 2025

PLD plus ifosfamide produced an ORR of 33% and a DCR of 83% in advanced soft tissue sarcoma, with manageable toxicity.

Anlotinib Plus Toripalimab Yields Antitumor Activity in Advanced Soft Tissue Sarcoma and Bone Sarcoma

August 13th 2025

Treatment with the combination of anlotinib and toripalimab produced durable efficacy in soft tissue sarcoma and bone sarcoma.

Dr Randall on the Importance of Multidisciplinary Efforts in Sarcoma Management

August 12th 2025

R. Lor Randall, MD, FACS, discusses how suboptimal access to multidisciplinary, coordinated care remains a critical barrier to optimal outcomes in sarcoma.

CLD-201 Viral Therapy Receives FDA Fast Track Designation for Soft Tissue Sarcoma

July 31st 2025

The first-in-class, allogeneic stem cell–loaded oncolytic virus CLD-201 was granted FDA fast track designation for the treatment of soft tissue sarcoma.

Vimseltinib Earns Positive CHMP Recommendation for TGCT

July 28th 2025

The EMA’s CHMP recommended the approval of vimseltinib for symptomatic tenosynovial giant cell tumor.

Global Disparities in Sarcoma Care Underscore Need for Timely Referral and Multidisciplinary Coordination

July 23rd 2025

R. Lor Randall, MD, FACS, discusses global disparities in sarcoma care during Sarcoma Awareness Month.

Dr Wilky on the Role of Personalized Therapy in GIST

July 16th 2025

Breelyn Wilky, MD, details personalized therapy approaches for the treatment of patients with GIST.

Dr Randall on Addressing Disparities in Access to Specialized Sarcoma Care

July 14th 2025

R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.

Imatinib Remains Standard of Care in GIST With ‘a Long Way to Go’

July 13th 2025

Breelyn Wilky, MD, discusses the importance of recognizing GIST Awareness Day and research towards moving the needle in the GIST treatment paradigm.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Dr D'Amato on Efficacy Data With Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

July 10th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Pexidartinib Shows Long-Term Safety and Efficacy in Symptomatic TGCT

July 9th 2025

Pexidartinib generated long-term responses in patients with symptomatic tenosynovial giant cell tumors.

Denosumab Biosimilar Earns European Approval in Advanced Malignancies Involving the Bone and Giant Cell Tumors of the Bone

July 2nd 2025

Denbrayce was approved in Europe for the treatment of skeletal-related events in advanced malignancies involving the bone and giant cell tumor of the bone.

Dr Vasquez on the Rationale for Investigating NAMPT Inhibition in Rhabdomyosarcoma

June 30th 2025

Juan Vasquez, MD, discussed unmet needs for patients with pediatric rhabdomyosarcoma that investigations of NAMPT inhibition may address.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.